 | |
- close
- close
| |||||||||
Industry (USD) Annual | ||||||||
|---|---|---|---|---|---|---|---|---|
| FISCAL YEAR ENDING |
 |
31-DEC 2004 |
31-DEC 2005 |
31-DEC 2006 |
31-DEC 2007 |
31-DEC 2008 |
 |
|
| Gross Profit | |
32.5B | 30.6B | 37.6B | 36.8B | 27.6B | |
|
| Operating Income | |
11.8B | 626M | 15.3B | 15.7B | 10.3B | |
|
| Total Revenues | |
39.0B | 37.3B | 45.5B | 45.1B | 35.0B | |
|
| Net Income | |
11.7B | 11.8B | 10.8B | 10.5B | 6.77B | |
|
| Gross Margin | |
78.2% | 78% | 78.4% | 76.6% | 73.7% |   | |
| Research and Development Expense | |
2.90B | 3.14B | 3.46B | 3.33B | 3.68B | | |
| R&D/Sales Ratio | |
14.5% | 14.5% | 14.9% | 14.6% | 15.1% | | |
| Number of Drugs | |
0 | 149 | 158 | 210 | 0 | | |
| Number of Drugs in Phase I | |
0 | 38.0 | 39.0 | 40.0 | 41.0 | | |
| Number of Drugs in Phase II | |
0 | 46.0 | 61.0 | 65.0 | 54.0 | | |
| Number of Drugs in Phase III | |
0 | 11.0 | 31.0 | 34.0 | 29.0 | | |
| Number of Drug Recalls | |
0 | 0 | 0 | 1.00 | 0 | | |
| Number of Drug Approvals | |
0 | 7.00 | 12.0 | 10.0 | 15.0 | | |
| New Drug Applications | |
0 | 0 | 9.00 | 10.0 | 9.00 | | |
| ||||||
|
|
